Acarbose: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
'''Acarbose''' is a drug used to treat type 2 [[diabetes mellitus]] and, in some countries, [[prediabetes]]. It is sold in Europe under the brand name '''Glucobay'''® ([[Bayer|Bayer AG]]), in North America as '''Precose'''® ([[Bayer|Bayer AG]]), and in Canada as '''Prandase'''® ([[Bayer|Bayer AG]]). It is an inhibitor of ''alpha glucosidase'', an enteric enzyme that releases [[glucose]] from larger [[carbohydrate]]s. The main side-effect is loose stool or [[diarrhea]], which limits its use, although these effects can be minimised by starting treatment with a low dose and titrating upwards. It is an effective [[anti-diabetic drug]]. |
'''Acarbose''' is a drug used to treat type 2 [[diabetes mellitus]] and, in some countries, [[prediabetes]]. It is sold in Europe under the brand name '''Glucobay'''® ([[Bayer|Bayer AG]]), in North America as '''Precose'''® ([[Bayer|Bayer AG]]), and in Canada as '''Prandase'''® ([[Bayer|Bayer AG]]). It is an inhibitor of ''alpha glucosidase'', an enteric enzyme that releases [[glucose]] from larger [[carbohydrate]]s. The main side-effect is loose stool or [[diarrhea]], which limits its use, although these effects can be minimised by starting treatment with a low dose and titrating upwards. It is an effective [[anti-diabetic drug]]. |
||
'''Acarbose''' inhibits enzymes needed to digest [[carbohydrates]]: |
'''Acarbose''' inhibits enzymes needed to digest [[carbohydrates]]: specifically [[alpha-glucosidase]] enzymes in the brush broder of the small intestines and it inhibits pancreatic alpha-amylase. [[Pancreatic]] [[alpha-amylase]] hydrolyzes complex starches to [[oligosaccharides]] in the lumen of the small intestine, whereas the membrane-bound intestinal [[alpha-glucosidases]] hydrolyze [[oligosaccharides]], [[trisaccharides]], and [[disaccharides]] to [[glucose]] and other [[monosaccharides]] in the small intestine. Inhibition of these enzyme systems reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. In [[diabetic]] patients, the short-term effect of these drugs therapies is to decrease current blood glucose levels: the long term effect is a small reduction in [[hemoglobin A1C]] level. (From Drug Therapy in Nursing, 2nd ed) |
||
== External links == |
== External links == |
||
Revision as of 00:21, 27 March 2006
Acarbose is a drug used to treat type 2 diabetes mellitus and, in some countries, prediabetes. It is sold in Europe under the brand name Glucobay® (Bayer AG), in North America as Precose® (Bayer AG), and in Canada as Prandase® (Bayer AG). It is an inhibitor of alpha glucosidase, an enteric enzyme that releases glucose from larger carbohydrates. The main side-effect is loose stool or diarrhea, which limits its use, although these effects can be minimised by starting treatment with a low dose and titrating upwards. It is an effective anti-diabetic drug.
Acarbose inhibits enzymes needed to digest carbohydrates: specifically alpha-glucosidase enzymes in the brush broder of the small intestines and it inhibits pancreatic alpha-amylase. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine, whereas the membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. Inhibition of these enzyme systems reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. In diabetic patients, the short-term effect of these drugs therapies is to decrease current blood glucose levels: the long term effect is a small reduction in hemoglobin A1C level. (From Drug Therapy in Nursing, 2nd ed)
External links
 | This medical treatment–related article is a stub. You can help Wikipedia by expanding it. |